Jonathon Kellerman - Allergan Plc Executive Vice President Chief Compliance Officer

President

Mr. Jonathon Kellerman was appointed as Executive Vice President Chief Compliance Officer of Actavis PLC. with effect from 22 December 2014. Mr. Kellerman joins Actavis from PwC where he was a partner in PwC Pharmaceutical and Life Sciences Advisory practice responsible for helping lead the firm Governance Risk Compliance practice including a global team of over 100 diverse professionals. Mr. Kellerman brings extensive experience in compliance and sales and marketing performance improvement including global antibriberyanticorruption program assessment design and implementation work building and implementing effective global compliance programs managing fraud investigations and remediation activities reengineering processes supporting key commercial and RD business activities and compliance controls and redesigning how companies engage health care professionals. He has also led major rapid response organizational and business process improvement initiatives across multiple business and support functions. Earlier in his career Mr. Kellerman worked in Healthcare Consulting for Zelenkofske Axelrod and in Research for Blank Rome since 2014.
Tenure 10 years
Phone862 261 7000
Webhttp://www.allergan.com
Kellerman is a recognized industry thought leader on the future of compliance strategy, organization and function visàvis a rapidly changing business model and regulatory landscape and was a frequent contributor to white papers, industry publications and conferences. He has a BA in Sociology from Franklin & Marshall College.

Allergan Plc Management Efficiency

The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Shane FitzwaterNeogen
43
Andy WattulaHudson Pacific Properties
48
Stewart BauckNeogen
59
Drew GordonHudson Pacific Properties
57
Michael SniderLGI Homes
53
Natalie TeearHudson Pacific Properties
N/A
Chuck WeHudson Pacific Properties
N/A
Jennifer RiceNeogen
55
Lori SilversteinBoston Properties
45
Jake StromanBoston Properties
N/A
James FergusonTeleflex Incorporated
N/A
Roger GrahamTeleflex Incorporated
N/A
Rachel EatonLGI Homes
42
Mark MozolaNeogen
59
Frank BurtBoston Properties
61
John DerenTeleflex Incorporated
N/A
Peter OtteniBoston Properties
N/A
Matthew JamesTeleflex Incorporated
N/A
Praneet MehrotraTeleflex Incorporated
N/A
Robert PesterBoston Properties
63
Cameron HicksTeleflex Incorporated
59
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people. Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Management Performance

Allergan Plc Leadership Team

Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Allergan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Allergan Plc

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Eastman Chemical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eastman Chemical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eastman Chemical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eastman Chemical to buy it.
The correlation of Eastman Chemical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eastman Chemical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eastman Chemical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eastman Chemical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Consideration for investing in Allergan Stock

If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Bonds Directory
Find actively traded corporate debentures issued by US companies
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets